mGlu receptors as potential targets for novel antidepressants
Sign Up to like & getrecommendations! Published in 2018 at "Current Opinion in Pharmacology"
DOI: 10.1016/j.coph.2018.02.001
Abstract: HighlightsmGlu2/3 antagonists exert ketamine‐like antidepressant effects in rodent models.mGlu2/3 antagonists shared some of their mechanisms with ketamine.mGlu5 NAMs exert antidepressant effects in rodent models.The mechanisms of mGlu5 NAMs may differ from those of ketamine.Antidepressant potential… read more here.
Keywords: novel antidepressants; mglu receptors; potential targets; receptor ... See more keywords
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Brain"
DOI: 10.1186/s13041-017-0293-z
Abstract: Support for the N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia has led to increasing focus on restoring proper glutamatergic signaling as an approach for treatment of this devastating disease. The ability of metabotropic glutamate (mGlu)… read more here.
Keywords: allosteric modulators; metabotropic glutamate; receptor; mglu receptors ... See more keywords
Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2019.00049
Abstract: Metabotropic glutamate (mGlu) receptors are considered as candidate drug targets for the treatment of schizophrenia. These receptors form a family of eight subtypes (mGlu1 to −8), of which mGlu1 and −5 are coupled to Gq/11,… read more here.
Keywords: schizophrenia; mglu receptors; disease; mglu3 receptors ... See more keywords